Compare Eli Lilly And Co (LLY) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Union Pacific Corporation — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while Union Pacific Corporation trades at $278.62 (market cap $165.27B). The key difference: Eli Lilly And Co is far larger — about 6.3× Union Pacific Corporation's market cap, and Union Pacific Corporation pays the higher dividend (2.04%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Union Pacific Corporation for 105 Days on average.
| LLY | UNP | |
|---|---|---|
Market Cap | $1.04T | $165.27B |
Volume | 3,064,878 | 1,474,117 |
Sector | Health | Industrials |
52-Week High | $1.28K | $310.62 |
52-Week Low | $799.57 | $216.37 |
Typical Hold Time | 93 Days | 105 Days |
Enterprise Value | $1.09T | $194.33B |
Dividend Yield | 0.59% | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Union Pacific (UNP) trades at $278.34, up 1.33% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 28.85% net margins and consistent earnings beats, while maintaining positive cash flow generation. Recent developments include deployment of battery-electric locomotives and progress on the Norfolk Southern combination, positioning the railroad for future growth.
The outlook remains positive with analyst consensus pointing to 19% upside potential to the $332.10 price target. Key opportunities include pricing power from high diesel costs shifting freight to rail, while risks center on merger uncertainty and fuel cost pressures on operating ratios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
